Efficacy of Pioglitazone on Macrovascular Outcome in Patients With Type 2 Diabetes
Status:
Completed
Trial end date:
2005-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether pioglitazone, once daily (QD), can delay
the time to death, heart attack, acute coronary syndrome, heart bypass surgery, stroke, leg
bypass surgery or amputation in patients with type 2 diabetes.